Polycythemia other diagnostic studies

Jump to navigation Jump to search

Polycythemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia other diagnostic studies

CDC on Polycythemia other diagnostic studies

Polycythemia other diagnostic studies in the news

Blogs on Polycythemia other diagnostic studies

Directions to Hospitals Treating Polycythemia

Risk calculators and risk factors for Polycythemia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]Zaida Obeidat, M.D.


Other Diagnostic Studies

The JAK2 1849G>T (617V>F) mutation has been detected in at least 90% of patients with polycythemia vera (PV). This mutation is strongly contributed with myeloproliferative disorders (MPDs). However, the presence of the mutation in 3 different MPDs raises the question of whether other molecular events or genetic modifiers influence the phenotype. Accumulating evidence suggests that the JAK2 mutation directly causes erythrocytosis in patients with PV.[1]

References

  1. Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, Larbret F; et al. (2007). "The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera". Blood. 110 (3): 1013–21. doi:10.1182/blood-2006-10-054940. PMID 17389763.

Template:WH Template:WS